Residue is a citation-first peptide encyclopedia: evidence grades, registered trials, PubChem identifiers and FDA status for each compound, every claim linked to its primary source. No prices, no vendors.https://residue.info/https://residue.info/c/afamelanotide/https://residue.info/c/afamelanotide/Afamelanotide, the drug once called Melanotan I, from primary sources: two randomized EPP trials in NEJM, the Scenesse implant approval and its safety record.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/aod-9604/https://residue.info/c/aod-9604/AOD-9604, the modified growth-hormone fragment, from primary sources: rodent fat-metabolism studies, an unpublished phase II program and FDA's concerns.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/bpc-157/https://residue.info/c/bpc-157/BPC-157 graded on the record: 35 of 36 studies in a 2025 review were preclinical, three small human pilots, a sub-30-minute half-life and FDA's concerns.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/bremelanotide/https://residue.info/c/bremelanotide/Bremelanotide (PT-141, Vyleesi) from primary sources: the RECONNECT phase 3 trials, nausea and blood-pressure findings, trial doses and the 2019 FDA approval.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/cagrilintide/https://residue.info/c/cagrilintide/Cagrilintide, the long-acting amylin analog, and CagriSema from primary sources: phase 2 and REDEFINE phase 3 results, side effects, half-life and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/cjc-1295/https://residue.info/c/cjc-1295/CJC-1295, the long-acting GHRH analog, from primary sources: two small human studies, a 5.8–8.1-day half-life, GH and IGF-1 effects and FDA's safety concerns.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/dsip/https://residue.info/c/dsip/DSIP (emideltide) from primary sources: small 1980s insomnia trials, a 1992 double-blind study that found little benefit, its unresolved biology and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/elamipretide/https://residue.info/c/elamipretide/Elamipretide (SS-31) from primary sources: TAZPOWER in Barth syndrome, the negative MMPOWER-3 trial, heart failure data and its 2025 FDA approval.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/epitalon/https://residue.info/c/epitalon/Epitalon (AEDG) graded on the record: telomerase effects in cell lines, mouse lifespan and tumor studies, one uncontrolled retinal report — and FDA's position.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/ghk-cu/https://residue.info/c/ghk-cu/GHK-Cu, the copper tripeptide, graded on the record: skin and wound biology, one 13-patient randomized study and FDA's injectable-route concern.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/ipamorelin/https://residue.info/c/ipamorelin/Ipamorelin from the primary literature: the first selective GH secretagogue, its single published human efficacy trial, animal data and FDA compounding status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/kisspeptin-10/https://residue.info/c/kisspeptin-10/Kisspeptin-10 from primary sources: human studies on LH, FSH and testosterone in men and women, a 2026 12-day trial, trial doses and FDA's Category 2 listing.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/kpv/https://residue.info/c/kpv/KPV, the α-MSH C-terminal tripeptide, from primary sources: mouse colitis studies via PepT1, nanoparticle delivery, skin-cell work — and no human data.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/ll-37/https://residue.info/c/ll-37/LL-37, the human cathelicidin, from primary sources: two venous leg ulcer trials (one positive, one negative), its biology and FDA's compounding concerns.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/melanotan-ii/https://residue.info/c/melanotan-ii/Melanotan II (MT-II) from primary sources: two small erection trials, a 3-man tanning pilot, case reports of melanoma and rhabdomyolysis, and FDA's position.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/mots-c/https://residue.info/c/mots-c/MOTS-c, the 16-residue mitochondrial-encoded peptide, from primary sources: mouse metabolism and aging studies, human plasma-level data, trials and FDA's view.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/retatrutide/https://residue.info/c/retatrutide/Retatrutide (LY3437943) explained from the primary literature: phase 2 and phase 3 TRIUMPH results, reported side effects, registered trials and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/selank/https://residue.info/c/selank/Selank (TP-7) from primary sources: a 62-patient anxiety study versus medazepam, proposed GABA and enkephalinase mechanisms, and FDA's position.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/semaglutide/https://residue.info/c/semaglutide/Semaglutide (Ozempic, Wegovy, Rybelsus) from primary sources: STEP and SELECT results, side-effect rates, 7-day half-life and FDA-approved indications.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/semax/https://residue.info/c/semax/Semax, the ACTH(4-7)-Pro-Gly-Pro heptapeptide, from primary sources: Russian ischemic-stroke studies, rat transcriptomics, BDNF findings and FDA's position.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/sermorelin/https://residue.info/c/sermorelin/Sermorelin (GHRH 1-29) from the primary literature: how it works, pediatric trial results, pharmacokinetics, side effects and Geref's discontinuation.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/tb-500/https://residue.info/c/tb-500/TB-500 is Ac-LKKTETQ, a fragment of thymosin beta-4. What the research shows for the fragment and the full protein, registered trials, and FDA's position.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/tesamorelin/https://residue.info/c/tesamorelin/Tesamorelin from primary sources: phase 3 visceral-fat results, liver-fat trials, side effects and its FDA approval for HIV-associated abdominal fat.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/thymosin-alpha-1/https://residue.info/c/thymosin-alpha-1/Thymosin alpha-1 (Tα1, thymalfasin) from primary sources: the 1,106-patient TESTS sepsis trial, hepatitis B trials, COVID-19 data and FDA's position.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/c/tirzepatide/https://residue.info/c/tirzepatide/Tirzepatide (Mounjaro, Zepbound) from the primary sources: SURPASS and SURMOUNT results, side-effect rates, ~5-day half-life and FDA-approved indications.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/afamelanotide-vs-melanotan-ii/https://residue.info/vs/afamelanotide-vs-melanotan-ii/Melanotan 1 (afamelanotide) vs Melanotan 2 from primary sources: structure, receptors, trials, FDA approval of one and case reports of harm for the other.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/aod-9604-vs-tesamorelin/https://residue.info/vs/aod-9604-vs-tesamorelin/AOD-9604 vs tesamorelin from primary sources: a growth-hormone fragment studied in rodents versus an FDA-approved GHRH analog for HIV abdominal fat.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/bpc-157-vs-tb-500/https://residue.info/vs/bpc-157-vs-tb-500/BPC-157 vs TB-500 from primary sources: origins, proposed mechanisms, each one's small human record, why TB-500's trials belong to thymosin β4, FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/bremelanotide-vs-melanotan-ii/https://residue.info/vs/bremelanotide-vs-melanotan-ii/PT-141 (bremelanotide) vs Melanotan II from primary sources: shared sequence, receptor targets, trials in women and men, side effects and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/cagrilintide-vs-semaglutide/https://residue.info/vs/cagrilintide-vs-semaglutide/Cagrilintide vs semaglutide from primary sources: amylin versus GLP-1 mechanisms, phase 2 dose data, the REDEFINE CagriSema trials, side effects and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/cjc-1295-vs-ipamorelin/https://residue.info/vs/cjc-1295-vs-ipamorelin/CJC-1295 vs ipamorelin from primary sources: a long-acting GHRH analog versus a ghrelin-receptor agonist, human pharmacology, safety and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/elamipretide-vs-mots-c/https://residue.info/vs/elamipretide-vs-mots-c/Elamipretide (SS-31) vs MOTS-c from primary sources: a cardiolipin binder with FDA accelerated approval versus a mitochondrial peptide with mouse data.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/retatrutide-vs-semaglutide/https://residue.info/vs/retatrutide-vs-semaglutide/Retatrutide vs semaglutide from primary sources: triple agonist versus GLP-1 agonist, TRIUMPH and STEP weight results, SELECT outcomes, safety and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/retatrutide-vs-tirzepatide/https://residue.info/vs/retatrutide-vs-tirzepatide/Retatrutide vs tirzepatide from primary sources: triple versus dual agonism, TRIUMPH and SURMOUNT weight results, side effects and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/selank-vs-semax/https://residue.info/vs/selank-vs-semax/Selank vs semax from primary sources: two synthetic heptapeptides ending in Pro-Gly-Pro, small studies in anxiety and stroke, mechanisms, FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/semaglutide-vs-tirzepatide/https://residue.info/vs/semaglutide-vs-tirzepatide/Semaglutide vs tirzepatide from primary sources: the SURMOUNT-5 and SURPASS-2 head-to-head trials, cardiovascular data, side effects, half-life and FDA labels.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/sermorelin-vs-ipamorelin/https://residue.info/vs/sermorelin-vs-ipamorelin/Sermorelin vs ipamorelin from primary sources: GHRH-receptor versus ghrelin-receptor agonism, the human trial record for each, safety notes and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/tesamorelin-vs-ipamorelin/https://residue.info/vs/tesamorelin-vs-ipamorelin/Tesamorelin vs ipamorelin from primary sources: GHRH versus ghrelin-receptor action, phase 3 versus single-trial evidence, side effects and FDA status.Mon, 19 Oct 2026 00:00:00 GMThttps://residue.info/vs/tesamorelin-vs-sermorelin/https://residue.info/vs/tesamorelin-vs-sermorelin/Tesamorelin vs sermorelin from primary sources: two GHRH analogs, their approved uses (Egrifta, Geref), trial results, pharmacology, safety and FDA status.Mon, 19 Oct 2026 00:00:00 GMT